Apellis Q4 product revenue driven by SYFOVRE sales

Apellis Pharmaceuticals

24/02/2026 12:12

Overview

Biopharmaceutical company reported Q4 product revenue of $190 mln, driven by SYFOVRE sales

Net income for 2025 was $22 mln, compared to a net loss in 2024

Company plans regulatory submission for SYFOVRE prefilled syringe in 2026

Outlook

Apellis projects full-year 2025 net product revenues of $689 mln

Company plans SYFOVRE prefilled syringe regulatory submission in first half of 2026

Apellis expects cash and projected revenues to fund operations to profitability

Result Drivers

SYFOVRE DEMAND - SYFOVRE saw a 17% increase in injections year-over-year, maintaining market leadership in geographic atrophy

EMPAVELI LAUNCH SUCCESS - EMPAVELI achieved strong early launch in C3G and IC-MPGN, with favorable payer access and 267 patient start forms

PIPELINE ADVANCEMENT - Apellis advanced its pipeline with ongoing trials and regulatory plans for SYFOVRE and EMPAVELI

Company press release: ID:nGNX3nzxMd

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Product Revenue
$190.34 mln
Q4 Net Income
-$58.95 mln
Q4 Basic EPS
$0.47
Q4 Operating Expenses
$251.06 mln
Q4 Operating Income
-$51.14 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 7 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Apellis Pharmaceuticals Inc is $31.50, about 40.2% above its February 23 closing price of $22.47

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)